Ophthalmology Devices and Drugs Market â€“ Emerging Market Trends, Global Future Forecasts, Challenges & Opportunities http://www.marketsandmarkets.com/Market-Reports/ophthalmology-drugs-and-devicesmarket-730.html
The “Ophthalmology Drugs & Devices Market (Contact Lens, OCT Scanner, IOL, Dry Eye, AMD, Glaucoma) Competitive Landscape & Global Forecasts To 2017" analyzes and studies the major market drivers, restraints, and opportunities in North America, Europe, Asia, and Rest of the World. Browse: 222 market data tables 517 pages And in-depth TOC on ͞Ophthalmology Drugs & Devices Market͟ Download The PDF Brochure@ http://www.marketsandmarkets.com/pdfdownload.asp?id=730 The global Ophthalmology Devices and Drugs Market is expected to generate the revenue worth of $52.6 billion by 2017.
The ophthalmology drugs and devices market is divided into four major segments, namely, surgical devices, diagnostic and monitoring devices, vision care, and drugs. The ophthalmology drugs and devices market is mainly driven by the increasing aging population, large pool of patients with eye diseases, changing demographics and geographical trends, and increased focus on combination therapies of drugs. Get The Sample Pages@ http://www.marketsandmarkets.com/requestsample.asp?id=730 There is also growing awareness of eye diseases in developing countries, which provides significant growth opportunities in this market. Technological advancement in devices is another factor driving the market. However, economic slowdown and drying pipeline of ophthalmology drugs is restricting the market.
North America is estimated to have the largest share in the global ophthalmology devices market in 2012, followed by Europe, and Asia. Developed geographies like North America and Europe are likely to grow at low CAGRs. On one hand, reasonably favorable reimbursement structures and government involvement is reducing economic costs associated with the disease, while on the other hand, economic slowdown and the eurozone debt crisis is hindering the growth of these geographies, though not to a great
Growth in the APAC market, especially China and India, is likely to be propelled by a largely
untapped patient base, gradually increasing awareness, rising disposable income, and focus of major players in this market. The drug market is mainly driven by retinal disorder and dry eye drugs, which show positive CAGRs in the forecast period.
The retinal disorder drug market was monopolized by Lucentis till 2011, which was responsible for the positive growth in this market. Eylea, which was launched in early 2012, will drive this market further, affecting the share of Lucentis and surpass its sales by 2016. Similar to the retinal disorder market, the dry eye drug market was also driven by one brand, Restasis.
The other brands like Hyalein and Diquas are prominent in Japan and Asian countries. To date, there is no pharmaceutical treatment approved in Europe for dry eye. However, pipeline products Cyclokat and SAR1118 (Lifitegrast) will soon change the situation. Most
of the major glaucoma drugs have lost patent protection or will do so soon, which will hamper the growth of this market. Moreover, only two drugs are in the late stage of clinical research, estimated for launch only in 2013.
The key players in the ophthalmology drug market are Alcon (U.S.), Allergan (U.S.), Merck (U.S.), Pfizer (U.S.), Roche (Switzerland), and Santen (Japan). In the devices field,
prominent players are Abbott Medical Optics (U.S.), Alcon, Bausch & Lomb, Inc. (U.S.), Carl Zeiss Meditec (Germany), Essilor (France), Johnson & Johnson (U.S.), Nidek (Japan), and Topcon (Japan).
Alcon is the leading player in the surgical devices business, whereas Topcon is the leader in
the diagnostic devices market. Each segment of ophthalmology is dominated by different players owing to their core competencies.
About MarketsandMarkets: MarketsandMarkets is the largest market research firm worldwide in terms of annually published premium market research reports. Serving 1700 global fortune enterprises with more than 1200 premium studies in a year, M&M is catering to a multitude of clients across 8 different industrial verticals. We specialize in consulting assignments and business research across high growth markets, cutting edge technologies and newer applications. Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model â€“ GEM". M&Mâ€™s flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. The new included chapters on Methodology and Benchmarking presented with high quality analytical infographics in our reports gives complete visibility of how the numbers have been arrived and defend the accuracy of the numbers. We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.
Contact Us Mr. Rohan MarketsandMarkets 701 Pike Street Suite 2175, Seattle, WA 98101, United States Telephone No : 1-888-600-6441 Email: firstname.lastname@example.org MarketsandMarkets Blog http://www.marketsandmarkets.com http://twitter.com/marketsmarkets http://www.linkedin.com/company/marketsandmarkets
Published on Feb 16, 2017
The ophthalmology drugs and devices market is divided into four major segments, namely, surgical devices, diagnostic and monitoring devices,...